
	Veracyte, operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists.
	
	The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
